[1]
|
Wiersinga, W.M., Poppe, K.G. and Effraimidis, G. (2023) Hyperthyroidism: Aetiology, Pathogenesis, Diagnosis, Man-agement, Complications, and Prognosis. The Lancet Diabetes Endocrinology, 11, 282-298.
https://doi.org/10.1016/S2213-8587(23)00005-0
|
[2]
|
Kahaly, G.J. (2020) Management of Graves Thyroidal and Extrathyroidal Disease: An Update. The Journal of Clinical Endocrinology and Metabolism, 105, 3704-3720. https://doi.org/10.1210/clinem/dgaa646
|
[3]
|
Bano, A., Gan, E., Addison, C., Narayanan, K., Weaver, J.U., Tsat-lidis, V. and Razvi, S. (2019) Age May Influence the Impact of TRAbs on Thyroid Function and Relapse-Risk in Pa-tients with Graves Disease. The Journal of Clinical Endocrinology and Metabolism, 104, 1378-1385. https://doi.org/10.1210/jc.2018-01738
|
[4]
|
Allahabadia, A., Daykin, J., Holder, R.L., Sheppard, M.C., Gough, S.C. and Franklyn, J.A. (2000) Age and Gender Predict the Outcome of Treatment for Graves’ Hyperthyroidism. The Journal of Clinical Endocrinology and Metabolism, 85, 1038-1042. https://doi.org/10.1210/jcem.85.3.6430
|
[5]
|
Suzuki, N., Noh, J.Y., Yoshimura, R., Mikura, K., Kinoshita, A., Su-zuki, A., Mitsumatsu, T., Hoshiyama, A., Fukushita, M., Matsumoto, M., Yoshihara, A., Watanabe, N., Sugino, K. and Ito, K. (2021) Does Age or Sex Relate to Severity or Treatment Prognosis in Graves’ Disease? Thyroid: Official Journal of the American Thyroid Association, 31, 1409-1415. https://doi.org/10.1089/thy.2020.0881
|
[6]
|
Struja, T., Feh-lberg, H., Kutz, A., Guebelin, L., Degen, C., Mueller, B. and Schuetz, P. (2017) Can We Predict Relapse in Graves’ Disease? Results from a Systematic Review and Meta-Analysis. European Journal of Endocrinology, 176, 87-97. https://doi.org/10.1530/EJE-16-0725
|
[7]
|
Liu, X., Shi, B. and Li, H. (2015) Valuable Predictive Features of Re-lapse of Graves’ Disease after Antithyroid Drug Treatment. Annales d’endocrinologie, 76, 679-683. https://doi.org/10.1016/j.ando.2015.08.004
|
[8]
|
Magri, F., Zerbini, F., Gaiti, M., Capelli, V., Ragni, A., Rotondi, M. and Chiovato, L. (2016) Gender Influences the Clinical Presentation and Long-Term Outcome of Graves Disease. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 22, 1336-1342.
https://doi.org/10.4158/EP161350.OR
|
[9]
|
Tun, N.N., Beckett, G., Zammitt, N.N., Strachan, M.W., Seckl, J.R. and Gibb, F.W. (2016) Thyrotropin Receptor Antibody Levels at Diagnosis and after Thionamide Course Predict Graves’ Disease Relapse. Thyroid: Official Journal of the American Thyroid Association, 26, 1004-1009. https://doi.org/10.1089/thy.2016.0017
|
[10]
|
Antonelli, A., Ferrari, S.M., Ragusa, F., Elia, G., Paparo, S.R., Ruffilli, I., Patrizio, A., Giusti, C., Gonnella, D., Cristaudo, A., Foddis, R., Shoenfeld, Y. and Fallahi, P. (2020) Graves’ Disease: Epidemiology, Genetic and Environmental Risk Factors and Viruses. Best Practice & Research Clinical Endocrinology & Metabolism, 34, Article ID: 101387.
https://doi.org/10.1016/j.beem.2020.101387
|
[11]
|
Kim, H.J., Hong, G., Hwang, J., Kazmi, S.Z., Kim, K.H., Kang, T., Swan, H., Cha, J., Kim, Y.S., Kim, K.U., Hann, H.J. and Ahn, H.S. (2023) Familial Risk of Graves Disease among First-Degree Relatives and Interaction with Smoking: A Population-Based Study. The Journal of Clinical Endocrinology and Metabolism, 108, e502-e511.
https://doi.org/10.1210/clinem/dgad083
|
[12]
|
Wang, P.W., Chen, I.Y., Juo, S.H., Hsi, E., Liu, R.T. and Hsieh, C.J. (2013) Genotype and Phenotype Predictors of Relapse of Graves’ Disease after Antithyroid Drug Withdrawal. European Thyroid Journal, 1, 251-258.
https://doi.org/10.1159/000342621
|
[13]
|
Glinoer, D., de Nayer, P., Bex, M. and Belgian Collaborative Study Group on Graves’ Disease (2001) Effects of L-Thyroxine Administration, TSH-Receptor Antibodies and Smoking on the Risk of Recurrence in Graves’ Hyperthyroidism Treated with Antithyroid Drugs: A Double-Blind Prospective Randomized Study. European Journal of Endocrinology, 144, 475-483. https://doi.org/10.1530/eje.0.1440475
|
[14]
|
Quadbeck, B., Roggenbuck, U., Janssen, O.E., Hahn, S., Mann, K., Hoermann, R. and Basedow Study Group (2006) Impact of Smoking on the Course of Graves’ Disease after Withdrawal of Antithyroid Drugs. Experimental and Clinical Endocri-nology & Diabetes: Official Journal, German Society of Endocrinology [and] German Diabetes Association, 114, 406-411. https://doi.org/10.1055/s-2006-924065
|
[15]
|
Mohlin, E., Filipsson Nyström, H. and Eliasson, M. (2014) Long-Term Prognosis after Medical Treatment of Graves’ Disease in a Northern Swedish Population 2000-2010. Euro-pean Journal of Endocrinology, 170, 419-427.
https://doi.org/10.1530/EJE-13-0811
|
[16]
|
Rosch, P.J. (1993) Stressful Life Events and Graves’ Disease. The Lan-cet (London, England), 342, 566-567.
https://doi.org/10.1016/0140-6736(93)91402-8
|
[17]
|
Vita, R., Lapa, D., Trimarchi, F. and Benvenga, S. (2015) Stress Triggers the Onset and the Recurrences of Hyperthyroidism in Patients with Graves’ Disease. Endocrine, 48, 254-263. https://doi.org/10.1007/s12020-014-0289-8
|
[18]
|
Topcu, C.B., Celik, O. and Tasan, E. (2012) Effect of Stressful Life Events on the Initiation of Graves’ Disease. International Journal of Psychiatry in Clinical Practice, 16, 307-311. https://doi.org/10.3109/13651501.2011.631016
|
[19]
|
Vos, X.G., Smit, N., Endert, E., Brosschot, J.F., Tijssen, J.G. and Wiersinga, W.M. (2009) Age and Stress as Determinants of the Severity of Hyperthyroidism Caused by Graves’ Disease in Newly Diagnosed Patients. European Journal of Endocrinology, 160, 193-199. https://doi.org/10.1530/EJE-08-0573
|
[20]
|
Weng, H., Tian, W.B., Xiao, Z.D. and Xu, L. (2023) Prediction for Re-currence Following Antithyroid Drug Therapy for Graves’ Hyperthyroidism. Archives of Endocrinology and Metabolism, 67, e000609.
https://doi.org/10.20945/2359-3997000000609
|
[21]
|
Chen, D.Y., Schneider, P.F., Zhang, X.S., He, Z.M., Jing, J. and Chen, T.H. (2012) Mental Health Status and Factors That Influence the Course of Graves’ Disease and Antithyroid Treatments. Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology [and] German Diabetes Association, 120, 524-528.
https://doi.org/10.1055/s-0032-1323807
|
[22]
|
Shi, H., Sheng, R., Hu, Y., Liu, X., Jiang, L., Wang, Z. and Cui, D. (2020) Risk Factors for the Relapse of Graves’ Disease Treated with Antithyroid Drugs: A Systematic Review and Me-ta-Analysis. Clinical Therapeutics, 42, 662-675.
https://doi.org/10.1016/j.clinthera.2020.01.022
|
[23]
|
Li, J., Cai, Y., Sun, X., Yao, D. and Xia, J. (2017) MiR-346 and TRAb as Predicative Factors for Relapse in Graves’ Disease within One Year. Hormone and Metabolic Research, 49, 180-184. https://doi.org/10.1055/s-0043-100116
|
[24]
|
Cappelli, C., Gandossi, E., Castellano, M., Pizzocaro, C., Agosti, B., Delbarba, A., Pirola, I., De Martino, E. and Rosei, E.A. (2007) Prognostic Value of Thyrotropin Receptor Antibodies (TRAb) in Graves’ Disease: A 120 Months Prospective Study. Endocrine Journal, 54, 713-720. https://doi.org/10.1507/endocrj.k06-069
|
[25]
|
Abraham, P., Avenell, A., McGeoch, S.C., Clark, L.F. and Bevan, J.S. (2010) Antithyroid Drug Regimen for Treating Graves’ Hyperthyroidism. The Cochrane Database of Systematic Reviews, 2010, CD003420.
https://doi.org/10.1002/14651858.CD003420.pub4
|
[26]
|
Li, J., Bai, L., Wei, F., Wei, M., Xiao, Y., Yan, W. and Wei, J. (2021) Effect of Addition of Thyroxine in the Treatment of Graves’ Disease: A Systematic Review. Frontiers in Endocrinology, 11, Article ID: 560157.
https://doi.org/10.3389/fendo.2020.560157
|
[27]
|
Razvi, S., Vaidya, B., Perros, P. and Pearce, S.H. (2006) What Is the Evidence behind the Evidence-Base? The Premature Death of Block-Replace Antithyroid Drug Regimens for Graves’ Disease. European Journal of Endocrinology, 154, 783-786. https://doi.org/10.1530/eje.1.02169
|
[28]
|
Vaidya, B., Wright, A., Shuttleworth, J., Donohoe, M., Warren, R., Brooke, A., Gericke, C.A. and Ukoumunne, O.C. (2014) Block & Replace Regime versus Titration Regime of Antithyroid Drugs for the Treatment of Graves’ Disease: A Retrospective Observational Study. Clinical Endocrinology, 81, 610-613. https://doi.org/10.1111/cen.12478
|
[29]
|
Hussain, Y.S., Hookham, J.C., Allahabadia, A. and Balasubramanian, S.P. (2017) Epidemiology, Management and Outcomes of Graves’ Disease-Real Life Data. Endocrine, 56, 568-578. https://doi.org/10.1007/s12020-017-1306-5
|
[30]
|
Liu, L., Lu, H., Liu, Y., Liu, C. and Xun, C. (2016) Predicting Relapse of Graves’ Disease Following Treatment with Antithyroid Drugs. Experimental and Therapeutic Medicine, 11, 1453-1458. https://doi.org/10.3892/etm.2016.3058
|
[31]
|
Liu, S., Miao, J.J., Zhou, X., Sun, Q. and Mao, X.M. (2022) High Levels of Thyroid Hormones Promote Recurrence of Graves’ Dis-ease via Overexpression of B-Cell-Activating Factor. Journal of Clinical Laboratory Analysis, 36, e24701.
https://doi.org/10.1002/jcla.24701
|
[32]
|
Subekti, I., Kartiko, G.J., Suhardi, Z.F., Muhadi and Wisnu, W. (2021) Se-rum TSH Level as Predictor of Graves’ Disease Recurrence Following Antithyroid Drug Withdrawal: A Systematic Re-view. PLOS ONE, 16, e0245978.
https://doi.org/10.1371/journal.pone.0245978
|
[33]
|
Liu, X., Qiang, W., Liu, X., Liu, L., Liu, S., Gao, A., Gao, S. and Shi, B. (2015) A Second Course of Antithyroid Drug Therapy for Recurrent Graves’ Disease: An Experience in Endocrine Practice. European Journal of Endocrinology, 172, 321-326. https://doi.org/10.1530/EJE-14-0704
|
[34]
|
Ahn, H.Y., Chung, Y.J. and Cho, B.Y. (2017) Serum 25-Hydroxyvitamin D Might Be an Independent Prognostic Factor for Graves Disease Recurrence. Medicine, 96, e7700. https://doi.org/10.1097/MD.0000000000007700
|
[35]
|
Park, S., Song, E., Oh, H.S., Kim, M., Jeon, M.J., Kim, W.G., Kim, T.Y., Shong, Y.K., Kim, D.M. and Kim, W.B. (2019) When Should Antithyroid Drug Therapy to Reduce the Relapse Rate of Hyperthyroidism in Graves’ Disease Be Discontinued? Endocrine, 65, 348-356. https://doi.org/10.1007/s12020-019-01987-w
|
[36]
|
Kim, D. (2017) The Role of Vitamin D in Thyroid Diseases. In-ternational Journal of Molecular Sciences, 18, Article No. 1949. https://doi.org/10.3390/ijms18091949
|
[37]
|
Kivity, S., Agmon-Levin, N., Zisappl, M., Shapira, Y., Nagy, E.V., Dankó, K., Szekanecz, Z., Langevitz, P. and Shoenfeld, Y. (2011) Vitamin D and Autoimmune Thyroid Diseases. Cellular & Molecular Immunology, 8, 243-247.
https://doi.org/10.1038/cmi.2010.73
|
[38]
|
Planck, T., Shahida, B., Malm, J. and Manjer, J. (2018) Vitamin D in Graves Disease: Levels, Correlation with Laboratory and Clinical Parameters, and Genetics. European Thyroid Journal, 7, 27-33. https://doi.org/10.1159/000484521
|
[39]
|
Ma, J., Wu, D., Li, C., Fan, C., Chao, N., Liu, J., Li, Y., Wang, R., Miao, W., Guan, H., Shan, Z. and Teng, W. (2015) Lower Serum 25-Hydroxyvitamin D Level Is Associated with 3 Types of Autoimmune Thyroid Diseases. Medicine, 94, e1639. https://doi.org/10.1097/MD.0000000000001639
|
[40]
|
Zhang, H., Liang, L. and Xie, Z. (2015) Low Vitamin D Status Is Associated with Increased Thyrotropin-Receptor Antibody Titer in Graves Disease. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 21, 258-263. https://doi.org/10.4158/EP14191.OR
|
[41]
|
Yasuda, T., Okamoto, Y., Hamada, N., Miyashita, K., Takaha-ra, M., Sakamoto, F., Miyatsuka, T., Kitamura, T., Katakami, N., Kawamori, D., Otsuki, M., Matsuoka, T.A., Kaneto, H. and Shimomura, I. (2013) Serum Vitamin D Levels Are Decreased in Patients without Remission of Graves’ Disease. Endocrine, 43, 230-232.
https://doi.org/10.1007/s12020-012-9789-6
|
[42]
|
Ke, W., Sun, T., Zhang, Y., He, L., Wu, Q., Liu, J. and Zha, B. (2017) 25-Hydroxyvitamin D Serum Level in Hashimoto’s Thyroiditis, but Not Graves’ Disease Is Relatively Deficient. Endocrine Journal, 64, 581-587.
https://doi.org/10.1507/endocrj.EJ16-0547
|
[43]
|
Wang, J., Lv, S., Chen, G., Gao, C., He, J., Zhong, H. and Xu, Y. (2015) Meta-Analysis of the Association between Vitamin D and Autoimmune Thyroid Disease. Nutrients, 7, 2485-2498. https://doi.org/10.3390/nu7042485
|
[44]
|
Xu, M.Y., Cao, B., Yin, J., Wang, D.F., Chen, K.L. and Lu, Q.B. (2015) Vitamin D and Graves’ Disease: A Meta-Analysis Update. Nutrients, 7, 3813-3827. https://doi.org/10.3390/nu7053813
|
[45]
|
Cho, Y.Y. and Chung, Y.J. (2020) Vitamin D Supplementation Does Not Prevent the Recurrence of Graves’ Disease. Scientific Reports, 10, Article No. 16. https://doi.org/10.1038/s41598-019-55107-9
|
[46]
|
Brix, T.H., Kyvik, K.O., Christensen, K. and Hegedüs, L. (2001) Evidence for a Major Role of Heredity in Graves’ Disease: A Population-Based Study of Two Danish Twin Cohorts. The Journal of Clinical Endocrinology and Metabolism, 86, 930-934. https://doi.org/10.1210/jcem.86.2.7242
|
[47]
|
Marinò, M., Latrofa, F., Menconi, F., Chiovato, L. and Vitti, P. (2015) Role of Genetic and Non-Genetic Factors in the Etiology of Graves’ Disease. Journal of Endocrinological Investigation, 38, 283-294.
https://doi.org/10.1007/s40618-014-0214-2
|
[48]
|
Vos, X.G., Endert, E., Zwinderman, A.H., Tijssen, J.G. and Wiersinga, W.M. (2016) Predicting the Risk of Recurrence before the Start of Antithyroid Drug Therapy in Patients with Graves’ Hyperthyroidism. The Journal of Clinical Endocrinology and Metabolism, 101, 1381-1389. https://doi.org/10.1210/jc.2015-3644
|
[49]
|
Badenhoop, K., Donner, H., Braun, J., Siegmund, T., Rau, H. and Usadel, K.H. (1996) Genetic Markers in Diagnosis and Prediction of Relapse in Graves’ Disease. Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology [and] German Diabetes Associ-ation, 104, 98-100.
https://doi.org/10.1055/s-0029-1211712
|
[50]
|
Dittmar, M. and Kahaly, G.J. (2005) Immunoregulatory and Suscep-tibility Genes in Thyroid and Polyglandular Autoimmunity. Thyroid: Official Journal of the American Thyroid Associa-tion, 15, 239-250.
https://doi.org/10.1089/thy.2005.15.239
|
[51]
|
Tomer, Y., Concepcion, E. and Greenberg, D.A. (2002) A C/T Sin-gle-Nucleotide Polymorphism in the Region of the CD40 Gene Is Associated with Graves’ Disease. Thyroid: Official Journal of the American Thyroid Association, 12, 1129-1135. https://doi.org/10.1089/105072502321085234
|
[52]
|
Park, Y.J., Chung, H.K., Park, D.J., Kim, W.B., Kim, S.W., Koh, J.J. and Cho, B.Y. (2000) Polymorphism in the Promoter and Exon 1 of the Cytotoxic T Lymphocyte Antigen-4 Gene Associated with Autoimmune Thyroid Disease in Koreans. Thyroid: Official Journal of the American Thyroid As-sociation, 10, 453-459.
https://doi.org/10.1089/thy.2000.10.453
|
[53]
|
Chatzigeorgiou, A., Lyberi, M., Chatzilymperis, G., Nezos, A. and Kamper, E. (2009) CD40/CD40L Signaling and Its Implication in Health and Disease. BioFactors (Oxford, England), 35, 474-483. https://doi.org/10.1002/biof.62
|
[54]
|
Wang, P.W., Liu, R.T., Juo, S.H., Wang, S.T., Hu, Y.H., Hsieh, C.J., Chen, M.H., Chen, I.Y. and Wu, C.L. (2004) Cytotoxic T Lymphocyte-Associated Molecule-4 Polymorphism and Re-lapse of Graves’ Hyperthyroidism after Antithyroid Withdrawal. The Journal of Clinical Endocrinology and Metabolism, 89, 169-173.
https://doi.org/10.1210/jc.2003-030854
|
[55]
|
Wang, P.W., Chen, I.Y., Liu, R.T., Hsieh, C.J., Hsi, E. and Juo, S.H. (2007) Cytotoxic T Lymphocyte-Associated Molecule-4 Gene Polymorphism and Hyperthyroid Graves’ Disease Relapse after Antithyroid Drug Withdrawal: A Follow-Up Study. The Journal of Clinical Endocrinology and Metabolism, 92, 2513-2518.
https://doi.org/10.1210/jc.2006-2761
|
[56]
|
Sahin, M., Erdogan, M.F. and Erdogan, G. (2005) Cytotoxic T Lym-phocyte-Associated Molecule-4 Polymorphisms in Turkish Graves’ Disease Patients and Association with Probability of Remission after Antithyroid Therapy. European Journal of Internal Medicine, 16, 352-355. https://doi.org/10.1016/j.ejim.2005.06.007
|
[57]
|
Kim, K.W., Park, Y.J., Kim, T.Y., Park, D.J., Park, K.S. and Cho, B.Y. (2007) Susceptible Alleles of the CD40 and CTLA-4 Genes Are Not Associated with the Relapse after Antithyroid Withdrawal in Graves’ Disease. Thyroid: Official Journal of the American Thyroid Association, 17, 1229-1234. https://doi.org/10.1089/thy.2007.0011
|
[58]
|
Bufalo, N.E., Dos Santos, R.B., Rocha, A.G., Teodoro, L., Romaldini, J.H. and Ward, L.S. (2021) Polymorphisms of the Genes CTLA4, PTPN22, CD40, and PPARG and Their Roles in Graves’ Disease: Susceptibility and Clinical Features. Endocrine, 71, 104-112. https://doi.org/10.1007/s12020-020-02337-x
|